75 related articles for article (PubMed ID: 21552955)
1. Growth of human tumor-cell lines in immunodeficient scid and immune reconstituted human-pbl-scid mice - an improved in-vivo model for the study of human malignancy.
Walker W
Int J Oncol; 1995 Nov; 7(5):1227-32. PubMed ID: 21552955
[TBL] [Abstract][Full Text] [Related]
2. The development of a novel immunotherapy model of human ovarian cancer in human PBL-severe combined immunodeficient (SCID) mice.
Walker W; Gallagher G
Clin Exp Immunol; 1995 Sep; 101(3):494-501. PubMed ID: 7664496
[TBL] [Abstract][Full Text] [Related]
3. [Establishment and comparison of two intraperitoneally transplanted human ovarian carcinoma models with immune reconstitution in severe combined immunodeficient mice].
Li Y; Cui H; Chang XH; Feng J; Fu TY; Feng YJ; Wei LH
Ai Zheng; 2004 Feb; 23(2):160-4. PubMed ID: 14960235
[TBL] [Abstract][Full Text] [Related]
4. Human peripheral blood lymphocyte reconstituted severe combined immunodeficient (hu-PBL-SCID) mice. A model for human islet allograft rejection.
Shiroki R; Poindexter NJ; Woodle ES; Hussain MS; Mohanakumar T; Scharp DW
Transplantation; 1994 Jun; 57(11):1555-62. PubMed ID: 8009588
[TBL] [Abstract][Full Text] [Related]
5. A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
Tsuchida M; Brown SA; Tutt LM; Tan J; Seehafer DL; Harris JP; Xun CQ; Thompson JS
Clin Transplant; 1997 Oct; 11(5 Pt 2):522-8. PubMed ID: 9361954
[TBL] [Abstract][Full Text] [Related]
6. Xenogeneic PBL-scid mice: their potential and current limitations.
Greenwood JD
Lab Anim Sci; 1993 Apr; 43(2):151-5. PubMed ID: 8320963
[TBL] [Abstract][Full Text] [Related]
7. The in vivo production of specific human antibodies by vaccination of human-PBL-SCID mice.
Walker W; Gallagher G
Immunology; 1994 Oct; 83(2):163-70. PubMed ID: 7530687
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model.
Schultes BC; Zhang C; Xue LY; Noujaim AA; Madiyalakan R
Hybridoma; 1999 Feb; 18(1):47-55. PubMed ID: 10211788
[TBL] [Abstract][Full Text] [Related]
9. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector.
Tanaka F; Abe M; Akiyoshi T; Nomura T; Sugimachi K; Kishimoto T; Suzuki T; Okada M
Cancer Res; 1997 Apr; 57(7):1335-43. PubMed ID: 9102222
[TBL] [Abstract][Full Text] [Related]
10. Specific antibody production to a recall or a neoantigen by SCID mice reconstituted with human peripheral blood lymphocytes.
Nonoyama S; Smith FO; Ochs HD
J Immunol; 1993 Oct; 151(7):3894-901. PubMed ID: 8376809
[TBL] [Abstract][Full Text] [Related]
11. Transplantation of a human ovarian cystadenocarcinoma into severe combined immunodeficient (SCID) mice--formation of metastases without significant alteration of the tumour cell phenotype.
Schumacher U; Adam E; Horny HP; Dietl J
Int J Exp Pathol; 1996 Oct; 77(5):219-27. PubMed ID: 8977374
[TBL] [Abstract][Full Text] [Related]
12. Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice.
Kapp U; Wolf J; von Kalle C; Tawadros S; Röttgen A; Engert A; Fonatsch C; Stein H; Diehl V
Ann Oncol; 1992 Sep; 3 Suppl 4():21-3. PubMed ID: 1450076
[TBL] [Abstract][Full Text] [Related]
13. The fate of human peripheral blood lymphocytes after transplantation into SCID mice.
Martino G; Anastasi J; Feng J; Mc Shan C; DeGroot L; Quintans J; Grimaldi LM
Eur J Immunol; 1993 May; 23(5):1023-8. PubMed ID: 8477797
[TBL] [Abstract][Full Text] [Related]
14. [Establishment of human retinoblastoma model in human immune reconstruction non-obese diabetic-severe combine immunodeficient mice].
Zhong XF; Ge J; Peng FH; Zhang B; Lin JX; Zhang WX; Li YP
Zhonghua Yan Ke Za Zhi; 2007 Aug; 43(8):739-43. PubMed ID: 18001574
[TBL] [Abstract][Full Text] [Related]
15. [Development of intraperitoneally transplantated human ovarian carcinoma model with immune reconstruction in severe combined immunodeficient mice].
Zhu H; Ye D; Chen H; Lu W; Xie X
Zhonghua Yi Xue Za Zhi; 2002 May; 82(9):630-3. PubMed ID: 12133487
[TBL] [Abstract][Full Text] [Related]
16. Growth and dissemination of human malignant melanoma cells in mice with severe combined immune deficiency.
Taylor CW; Grogan TM; Lopez MH; Leong SP; Odeleye A; Feo-Zuppardi FJ; Hersh EM
Lab Invest; 1992 Jul; 67(1):130-7. PubMed ID: 1625443
[TBL] [Abstract][Full Text] [Related]
17. Mouse strain and conditioning regimen determine survival and function of human leucocytes in immunodeficient mice.
Tournoy KG; Depraetere S; Pauwels RA; Leroux-Roels GG
Clin Exp Immunol; 2000 Jan; 119(1):231-9. PubMed ID: 10606988
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the adoptive transfer of delayed hypersensitivity and T cell repertoire in severe combined immunodeficiency mice reconstituted with human lymphocytes.
Mancia L; Mariani F; Mattei M; Montesano C; Placido R; Colizzi V; Salerno A; Bellavia A
Folia Biol (Praha); 1994; 40(6):411-30. PubMed ID: 7589700
[TBL] [Abstract][Full Text] [Related]
19. [Development of HPV16 positive cervical cancer model in the hu-PBL-SCID mouse and its immunological features].
Liang ZX; Cheng Q; Chen HZ; Xie X; Ye DF
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(17):1465-9. PubMed ID: 15500747
[TBL] [Abstract][Full Text] [Related]
20. Engraftment of human peripheral blood leukocytes into severe combined immunodeficient mice results in the long term and dynamic production of human xenoreactive antibodies.
Williams SS; Umemoto T; Kida H; Repasky EA; Bankert RB
J Immunol; 1992 Oct; 149(8):2830-6. PubMed ID: 1401915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
